Stifel Nicolaus reiterated their hold rating on shares of Geron Corporation (NASDAQ:GERN) in a report published on Friday. Stifel Nicolaus currently has a $2.50 price target on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on GERN. Zacks Investment Research cut Geron Corporation from a buy rating to a hold rating in a report on Tuesday, July 11th. BidaskClub cut Geron Corporation from a hold rating to a sell rating in a report on Saturday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Geron Corporation currently has an average rating of Hold and an average price target of $3.75.
Shares of Geron Corporation (GERN) traded down $0.05 during trading hours on Friday, hitting $2.12. The stock had a trading volume of 935,088 shares, compared to its average volume of 1,275,479.
Geron Corporation (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.40 million. During the same period in the prior year, the company earned ($0.02) EPS. The firm’s revenue was down 96.8% compared to the same quarter last year. equities research analysts predict that Geron Corporation will post -0.18 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/11/04/geron-corporations-gern-hold-rating-reaffirmed-at-stifel-nicolaus.html.
A number of large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its holdings in Geron Corporation by 1.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 58,056 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 1,000 shares in the last quarter. Creative Planning grew its holdings in Geron Corporation by 1.3% in the 2nd quarter. Creative Planning now owns 103,213 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 1,345 shares in the last quarter. IHT Wealth Management LLC purchased a new stake in Geron Corporation in the 2nd quarter valued at $122,000. Tudor Investment Corp ET AL grew its holdings in Geron Corporation by 12.1% in the 1st quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,669 shares in the last quarter. Finally, American International Group Inc. grew its holdings in Geron Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 92,964 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 6,140 shares in the last quarter. Institutional investors own 38.78% of the company’s stock.
About Geron Corporation
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
What are top analysts saying about Geron Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Corporation and related companies.